ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
PR Newswire•02/11/2026•07:15 ET
0
Key Highlights
- ➤ADC Therapeutics (ADCT) will release Q3 2026 financial results November 9, 2026
- ➤ZYNLONTA holds accelerated FDA approval for relapsed or refractory diffuse large B-cell lymphoma
- ➤FDA raised serious concerns about LOTIS-5 results at a recent pre-sBLA meeting
- ➤Company expects cash runway into 2029, subject to stated risks and uncertainties
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 PR Newswire
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company will report full financial results for the third quarter of 2026 through a press release on Monday, November 9, 2026. The press release will be available in the News section of the Company's website, https://ir.adctherapeutics.com/news .
Get started
Create a free account to read the full story.